Intuitive Surgical (ISRG) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
13 Mar, 2026Executive summary
Annual meeting scheduled for April 30, 2026, with voting available online and virtually for shareholders.
Shareholders are encouraged to review proxy materials and vote on key proposals affecting governance and compensation.
Voting matters and shareholder proposals
Election of ten directors, with each nominee recommended by the board for approval.
Advisory vote on executive compensation for named executive officers.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Approval sought for amendment and restatement of the 2010 Incentive Award Plan.
Board of directors and corporate governance
Ten director nominees listed, including individuals with diverse backgrounds in technology, healthcare, and business.
Board recommends voting in favor of all director nominees.
Latest events from Intuitive Surgical
- Shareholders to vote on board, pay, auditor, and equity plan amid strong growth and governance.ISRG
Proxy Filing13 Mar 2026 - Board elections, strong financial growth, and all management proposals approved; shareholder proposals rejected.ISRG
AGM 20253 Feb 2026 - Q2 revenue up 14% to $2.01B–$2.2B, driven by strong procedure and system growth.ISRG
Q2 20243 Feb 2026 - Strong 2025 growth and da Vinci 5 adoption drive continued expansion into 2026.ISRG
Q4 202522 Jan 2026 - Da Vinci 5 launch drives strong placements and positive feedback, supporting robust financial outlook.ISRG
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 2024 revenue up 17% to $2.04B, net income up 36% to $565M, with strong system growth.ISRG
Q3 202419 Jan 2026 - Record growth, innovation, and digital expansion set the stage for global priorities in 2026.ISRG
44th Annual J.P. Morgan Healthcare Conference16 Jan 2026 - Da Vinci 5 launch, innovation, and global growth drive momentum in minimally invasive care.ISRG
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Q4 2024 revenue up 25% with strong da Vinci growth; 2025 outlook cautious on margins.ISRG
Q4 20249 Jan 2026